Human CXCL17/VCC-1 Alexa Fluor® 647-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # IC4207R
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Leu24-Leu119
Accession # Q6UXB2
Specificity
Clonality
Host
Isotype
Applications for Human CXCL17/VCC-1 Alexa Fluor® 647-conjugated Antibody
Intracellular Staining by Flow Cytometry
Sample: A549 human lung carcinoma cell line fixed with paraformaldehyde and permeabilized with saponin
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: CXCL17/VCC-1
CXCL17, also known as dendritic cell and monocyte chemokine-like protein (DMC) and VEGF-correlated chemokine-1 (VCC-1), is a secreted molecule with a size and predicted three-dimensional folding pattern similar to that of chemokines CXCL8/IL-8 and CXCL14/BRAK (1, 2). It has no predicted N-glycosylation site. Cleavage of a 23 amino acid (aa) signal sequence yields the mature 96 aa human CXCL17. CXCL17 is constitutively produced by airway and intestinal epithelium (1). It induces the chemotaxis of quiescent, but not LPS-activated peripheral blood monocytes and dendritic cells (1). CXCL17 expression is increased in endothelial cells when they are induced to form tubes in vitro (2). Transgenic overexpression in NIH3T3 cells causes upregulation of proteins such as VEGF and FGF basic, and increases cell growth rate and tumorigenicity (2). CXCL17, plus two other chemokines that play roles in angiogenesis, CXCL1/GRO and CXCL8/IL-8, show a correlated expression pattern with VEGF in primary lung, breast and esophageal tumors (2). CXCL17 is, therefore, suggested to play a role in tumor angiogenesis. Mature human CXCL17 shares 73%, 71% and 64% amino acid sequence identity with bovine, mouse and rat CXCL17, respectively.
References
- Pisabarro, M.T. et al. (2006) J. Immunol. 176:2069.
- Weinstein, E.J. et al. (2006) Biochem. Biophys. Res. Commun. 350:74.
Alternate Names
Gene Symbol
UniProt
Additional CXCL17/VCC-1 Products
Product Documents for Human CXCL17/VCC-1 Alexa Fluor® 647-conjugated Antibody
Product Specific Notices for Human CXCL17/VCC-1 Alexa Fluor® 647-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only